Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: An immunohistochemical study;Metaloproteinazy macierzy zewnątrzkomórkowej MMP1, MMP2, MMP9 oraz ich inhibitory tkankowe TIMP1, TIMP2, TIMP3 w rakach głowy i szyi: badanie immunohistochemiczne

Otolaryngologia Polska

Volumn 70, Issue 3, 2016, Pages 32-43

  Pietruszewska, Wioletta ^a   Bojanowska Poźniak, Katarzyna ^a   Kobos, Józef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Head and neck cancer; Metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

FORMALDEHYDE; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 15; MONOCLONAL ANTIBODY; PARAFFIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DIFFUSION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; NODAL METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; STAINING; STROMA CELL; SURGICAL TECHNIQUE; SURVIVAL RATE; TUMOR CELL; UNIVARIATE ANALYSIS; ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; POLAND; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SQUAMOUS CELL; POLAND; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84975091191     PISSN: 00306657     EISSN: None     Source Type: Journal    
DOI: 10.5604/00306657.1202546     Document Type: Article

References (57)

1. Alshenawy H.A.: Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths. Ann. Diagn. Pathol. 2010; 14: 387-395.
2. Bartlett R.S., Heckman W.W., Isenberg J., Thibeault S.L., Dailey S.H.: Genetic characterization of vocal fold lesions: leukoplakia and carcinoma. Laryngoscope. 2012; 122: 336-342.
3. Bian J., Wang Y., Smith M.R., Kim H., Jacobs C., Jackman J., Kung H.F., Colburn N.H., Sun Y.: Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP3). Carcinogenesis. 1996; 17: 1805-1811.
4. Brinckerhoff C.E., Rutter J.L., Benbow U.: Interstitial collagenases as markers of tumor progression. Clin. Cancer Res. 2000; 6: 4823-4830.
5. Chuang C.K., Pang S.T., Chuang T.J., Liao S.K.: Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma. Oncol. Lett. 2010; 1: 691-695.
6. Danilewicz M., Sikorska B., Wągrowska-Danilewicz M.: Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in head and neck cancer. Med. Sci. 2003; MT, Mon.: 42-47.
7. De Carvalho A.C., Kowalski L.P., Campos A.H., Soares F.A., Carvalho A.L., Vettore A.L.: Clinical significance of molecular alterations in histologically negative surgical margins of head and neck cancer patients. Oral. Oncol. 2012; 48: 240-248.
8. Faber A., Sauter A., Hoedt S., Hoermann K., Erben P., Hofheinz R.D., Sommer U., Stern-Straeter J., Schultz D.J.: Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma. Oncol. Rep. 2012; 28: 172-178.
9. Fielding J., Scholefield J., Stuart R.: A randomized double-bind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 2000; 19: 240.
10. Franchi A., Santucci M., Masini E., Sardi I., Paglierani M., Gallo O.: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95. 2002: 1902-1910.
11. García M.F., González-Reyes S., González L.O., Junquera S., Berdize N., Del Casar J.M., Medina M., Vizoso F.J.: Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int. J. Exp. Pathol. 2010; 91: 324-334.
12. Hałoń A., Nowak-Markwitz E., Donizy P., Matkowski R., Maciejczyk A., Gansukh T., Györffy B., Spaczyński M., Zabel M., Lage H., Surowiak P.: Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. J. Histochem. Cytochem. 2012; 60: 491-501.
13. Hayakawa T., Yamashita K., Ochuchi E., Shinagawa A.: Cell growth promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP2). J. Cell Sci. 1994; 107: 2373-2379.
14. Heissenberg M.C., Gorogh T., Lippert B.M., Werner J.A.: Metalloproteinases and their inhibitors in squamous cell carcinoma of the hypopharynx: indicators of individual tumor aggressiveness. Otolaryngol. Pol. 1998; 52: 521-526.
15. Henriques A.C., de Matos F.R., Galvão H.C., Freitas R.de A.: Immunohistochemical expression of MMP-9 and VEGF in squamous cell carcinoma of the tongue. J. Oral. Sci. 2012; 54: 105-111.
16. Herszényi L., Hritz I., Lakatos G., Varga M.Z., Tulassay Z.: The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int. J. Mol. Sci. 2012; 16: 13240-13263.
17. Hewitt R., Dano K.: Stromal cell expression of components of matrix-degrading protease system in human cancer. Enzyme Protein. 1996; 49: 163-173.
18. Hoekstra R., Eskens F.A., Verweij J.: Matrix metalloprotinase inhibitors: current developments and future perspectives. Oncologist. 2001, 6:415-427.
19. Hrabec E., Strȩk M.: Tissue inhibitors of matrix metalloproteinases. Their roles in tissue remodeling and cell growth. Current Pneumonol. 1997; 1: 30-36.
20. Imren S., Kohn D.B., Shimada H., Blavier L., DeClerck Y.A.: Overexpression of tissue inhibitor of metalloproteinases-2 in vivo by retroviral mediated gene transfer inhibits tumor growth and invasion. Cancer Res. 1996; 56: 2891-2895.
21. Jeffery N., McLean M.H., El-Omar E.M., Murray G.I.: The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathol. 2009; 54: 820-828.
22. Johansson A.C., Ansell A., Jerhammar F., Lindh M.B., Grénman R., Munck-Wikland E., Östman A., Roberg K.: Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Mol Cancer Res. 2012; 10: 1158-1168.
23. Katayama A., Bandoh N., Kishibe K., Takahara M., Ogino T., Nonaka S., Harabuchi Y.: Expression of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastase and prognosis. Clin. Cancer Res. 2004; 10: 634-640.
24. Kato K., Hara A., Kuno T., Kitaori N., Huilan Z., Mori H., Toida M., Shibata T.: Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. J. Cancer Res. Clin. Oncol. 2005; 131: 340-346.
25. Khokha R., Zimmer M.J., Graham C.H., Lala P.K., Waterhouse P.: Suppresion of invasion of tissue inhibitor of metalloproteinase-1 (TIMP1) in B16F10 melanoma cells. J. Natl. Cancer Inst. 1992; 84: 1017-1022.
26. Krȩcicki T., Zalesska-Krȩcicka M., Jeleń M., Szkudlarek T., Horobiowska M.: Expression of type IV collagen and matrix metalloproteinase-2 (type IV collagenase) in relation to nodal status in head and neck cancer. Clin. Otolaryngol. 2001; 26: 469-472.
27. Kubben F.J., Sier C.M., van Duijn W., Griffioen G., Hanemaaijer R., van de Velde C.J., van Krieken J.H., Lamers C.B., Verspaget H.W.: Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br. J. Cancer. 2006; 94: 1035-1040.
28. Kurahara S., Shinohara M., Ikebe T., Nakamura S., Beppu M., Hiraki A., Takeuchi H., Shirasuna K.: Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck. 1999; 21: 627-638.
29. Leighl N.B., Paz-Ares L., Douillard J., Peschel C., Arnold A., Depierre A., Santoro A., Betticher D.C., Gatzemeier U., Jassem J., Crawford J., Tu D., Bezjak A., Humphrey J.S., Voi M., Galbraith S., Hann K., Seymour L., Shepherd F.A.: Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J. Clin. Oncol. 2005; 23: 2831-2839.
30. Lu C.C., Yang J.S., Chiang J.H., Hour M.J., Amagaya S., Lu K.W., Lin J.P., Tang N.Y., Lee T.H., Chung J.G.: Inhibition of invasion and migration by newly synthesized quinazolinone MJ-29 in human oral cancer CAL 27 cells through suppression of MMP-2/9 expression and combined down-regulation of MAPK and AKT signaling. Anticancer Res. 2012; 32: 2895-2903.
31. Maekawa K., Sato H., Furukawa M., Yoshizaki T.: Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model. Clin. Exp. Metastasis. 2002; 19:513-518.
32. Mallis A., Teymoortash A., Mastronikolis N.S., Werner J.A., Papadas T.A.: MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur. Arch. Otorhinolaryngol. 2012; 269: 639-642.
33. Mallya S.K., VanWart H.E.: Mechanism of human neutrophil collagenase by gold(I) chrysotherapeutic compounds. Interaction at a heavy metal binding site. J. Biol. Chem. 1989; 264: 1594-1601.
34. Miyake H., Muramaki M., Kurahashi T., Takenaka A., Fujisawa M.: Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol. 2010; 28: 145-151.
35. Mönig S.P., Baldus S.E., Hennecken J.K., Spiecker D.B., Grass G., Schneider P.M., Thiele J., Dienes H.P., Hölscher A.H.: Expression of MMP2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathol. 2001; 39: 597-602.
36. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M.: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 2000; 18: 1135-1149.
37. O-charoentrat P., Rhys-Evans P.H., Eccles S.A.: Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2001; 127: 813-820.
38. Ondruschka C., Buhtz P., Motsch C., Freigang B.: Prognostic value of MMP2,-9 and TIMP1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinoma. Pathol. Res. Pract. 2002; 198: 506-509.
39. Pesta M., Kulda V., Kucera R., Pesek M., Vrzalova J., Liska V., Pecen L., Treska V., Safranek J., Prazakova M., Vycital O., Bruha J., Holubec L., Topolcan O.: Prognostic significance of TIMP-1 in non-small cell lung cancer. Anticancer Res. 2011; 31: 4031-4038.
40. Phuphanich S., Levin V.A., Yung W.: A multicenter, randomized, double-blind, placebo controlled trial of marimastat in patients with glioblastoma multiforme or gliosarcoma following completion of conventional first-line treatment. Proc. Am. Soc. Clin. Oncol. 2001; 20: 52.
41. Ranogajec I., Jakić-Razumović J., Puzović V., Gabrilovac J.: Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med. Oncol. 2012; 29: 561-569.
42. Redondo P., Lloret P., Idoate M., Inogest S.: Expression and serum levels of MMP2 and MMP9 during human melanoma progression. Clin. Exp Dermatol. 2005; 30: 541-545.
43. Rosemurgy A., Buckels J., Charnley R.: A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 261.
44. Ruokolainen H., Paakko P., Turpeenniemi-Hujanen T.: Tissue and circulating immunoreactive protein for MMP2 and TIMP2 in head and neck squamous cell carcinoma - tissue immunoreactivity predicts aggressive clinical course. Mod. Pathol. 2006; 19: 208-217.
45. Scurry W.C., Stack B.C.: Role of metalloproteins in the clinical management of head and neck squamous cell carcinoma. Head and Neck Surg. 2007; 29: 1144-1155.
46. Selzer M.G., Zhu B., Block N.L., Lokeshwar B.L.: CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann NY Acad. Sci. 1999; 878: 678-688.
47. Snuderl M., Chi S.N., De Santis S.M., Stemmer-Rachamimov A.O., Betensky R.A., De Girolami U., Kieran M.W.: Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J. Neuropathol. Exp. Neurol. 2008; 67: 911-920.
48. Sparano J.A., Bernardo P., Stephenson P., Gradishar W.J., Ingle J.N., Zucker S., Davidson N.E.: Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196. J. Clin. Oncol. 2004; 22: 4683-4690.
49. Sternlicht M.D., Bergers G.: Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerging Ther Targets. 2000; 4: 609-633.
50. Sternlicht M.D., Werb Z.: How matrix metalloproteinases regulate cell behavior. Annu Rev. Cell Dev. Biol. 2001; 17: 463-517.
51. Sterz C.M., Kulle C., Dakic B., Makarova G., Böttcher M.C., Bette M., Werner J.A., Mandic R.: A basal-cell-like compartment in head and neck squamous cell carcinomas represents the invasive front of the tumor and is expressing MMP-9. Oral. Oncol. 2010; 46: 116-122.
52. Stott-Miller M., Houck J.R., Lohavanichbutr P., Méndez E., Upton M.P., Futran N.D., Schwartz S.M., Chen C.: Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2011; 20: 2628-2636.
53. Sullu Y., Demirag G.G., Yildirim A., Karagoz F., Kandemir B.: Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol. Res. Pract. 2011; 15: 747-753.
54. Väisänen A., Kuvaja P., Kallioinen M., Turpeenniemi-Hujanen T.: A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum. Pathol. 2011; 42: 1103-1111.
55. Xiang Z.L., Zeng Z.C., Tang Z.Y., Fan J., Sun H.C., Tan Y.S.: Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma. Mol Biol. Rep. 2011; 38: 3531-3539.
56. Xie M., Sun J., Li Y.: Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope. 2004; 114: 2243-2248.
57. Zhang L., Shi J., Feng J., Klocker H., Lee C., Zhang J.: Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer and Prostatic Diseases. 2004; 7: 327-332.